Every GLP-1 Name You'll Encounter: Brand Names, Generic Molecules, Compounded Versions, and What Each One Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• There are 11 FDA-approved GLP-1 receptor agonist medications across 8 brand names, but only 3 generic molecules (semaglutide, tirzepatide, liraglutide) account for 94% of prescriptions in 2026
• "GLP-1" is the drug class; semaglutide and tirzepatide are the active ingredients; Ozempic, Wegovy, Mounjaro, and Zepbound are brand names owned by pharmaceutical companies
• Compounded versions use the same generic molecule names (compounded semaglutide, compounded tirzepatide) but are not FDA-approved and cannot legally use brand names
• International research uses generic names exclusively, which is why you'll see "semaglutide" in studies but "Ozempic" or "Wegovy" in U.S. advertising depending on the approved indication

Direct answer (40-60 words)

GLP-1 names fall into three categories: the drug class (GLP-1 receptor agonists), the generic molecule (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide, semaglutide oral), and the brand name (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, Bydureon, Adlyxin, Rybelsus). The same molecule often has multiple brand names for different approved uses.

Table of contents

1. The naming hierarchy: class, molecule, and brand
2. The complete FDA-approved GLP-1 list (2026)
3. Why the same molecule has different brand names
4. Compounded GLP-1 names and what "compounded semaglutide" actually means
5. Dual agonists vs pure GLP-1s: the tirzepatide distinction
6. International and research names you'll see in studies
7. What most articles get wrong about "generic" GLP-1s
8. The FormBlends naming convention for compounded products
9. Discontinued GLP-1 names and why they matter
10. How to decode a GLP-1 prescription
11. When brand names legally matter and when they don't
12. FAQ

The naming hierarchy: class, molecule, and brand

Understanding GLP-1 names requires understanding three distinct levels of pharmaceutical nomenclature:

Level 1: Drug class. GLP-1 receptor agonists (also called GLP-1 RA, GLP-1 analogs, or incretin mimetics). This is the broadest category. It describes the mechanism: medications that activate the GLP-1 receptor to increase insulin secretion, slow gastric emptying, and reduce appetite. Every medication in this article belongs to this class.

Level 2: Generic molecule (International Nonproprietary Name, or INN). This is the actual chemical compound. Examples: semaglutide, tirzepatide, liraglutide, dulaglutide. The INN is assigned by the World Health Organization and is the same worldwide. Research papers, clinical trials, and compounding pharmacies use this name. It's not owned by anyone.

Level 3: Brand name (proprietary name). This is the trademark owned by the pharmaceutical manufacturer. Examples: Ozempic, Wegovy, Mounjaro, Zepbound. The same molecule can have multiple brand names if approved for different indications or marketed in different countries. Brand names are protected intellectual property and cannot be used by compounding pharmacies or generic manufacturers without license.

The confusion happens because U.S. direct-to-consumer advertising uses brand names almost exclusively, while medical literature uses generic molecule names. A patient sees a Wegovy commercial, then reads a research paper about "semaglutide 2.4 mg for obesity" and doesn't realize they're the same drug.

The complete FDA-approved GLP-1 list (2026)

Generic molecule	Brand name(s)	Manufacturer	FDA approval year	Approved indication(s)	Dosing frequency
Exenatide	Byetta	AstraZeneca	2005	Type 2 diabetes	Twice daily injection
Exenatide extended-release	Bydureon, Bydureon BCise	AstraZeneca	2012	Type 2 diabetes	Once weekly injection
Liraglutide	Victoza	Novo Nordisk	2010	Type 2 diabetes	Once daily injection
Liraglutide	Saxenda	Novo Nordisk	2014	Obesity (weight management)	Once daily injection
Albiglutide	Tanzeum (discontinued 2018)	GSK	2014	Type 2 diabetes	Once weekly injection
Dulaglutide	Trulicity	Eli Lilly	2014	Type 2 diabetes	Once weekly injection
Lixisenatide	Adlyxin	Sanofi	2016	Type 2 diabetes	Once daily injection
Semaglutide (injectable)	Ozempic	Novo Nordisk	2017	Type 2 diabetes	Once weekly injection
Semaglutide (oral)	Rybelsus	Novo Nordisk	2019	Type 2 diabetes	Once daily oral tablet
Semaglutide (injectable, higher dose)	Wegovy	Novo Nordisk	2021	Obesity (weight management)	Once weekly injection
Tirzepatide	Mounjaro	Eli Lilly	2022	Type 2 diabetes	Once weekly injection
Tirzepatide	Zepbound	Eli Lilly	2023	Obesity (weight management)	Once weekly injection

As of April 2026, there are 11 distinct FDA-approved products across 8 brand names still on the market (Tanzeum was discontinued in 2018). The market is dominated by three molecules:

• Semaglutide (Ozempic, Wegovy, Rybelsus): 68% of GLP-1 prescriptions in the U.S. as of Q4 2025 (IQVIA data)
• Tirzepatide (Mounjaro, Zepbound): 26% of prescriptions
• Dulaglutide (Trulicity): 4% of prescriptions

The remaining products (liraglutide, exenatide, lixisenatide) account for approximately 2% combined, mostly legacy patients who started treatment before 2020.

Why the same molecule has different brand names

Pharmaceutical companies create separate brand identities for the same molecule when it's approved for different indications. This serves three purposes:

1. Regulatory separation. The FDA approves drugs for specific indications. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at doses up to 2.4 mg weekly. They contain identical semaglutide, but the approved use, dosing schedule, and clinical trial data supporting each approval are different. Separate brand names make the distinction clear.

2. Insurance and formulary management. Insurance companies often cover diabetes medications under pharmacy benefits but require prior authorization or exclude coverage entirely for weight-loss medications. Separate brand names allow payers to set different coverage policies. A patient might have Ozempic covered as a diabetes drug but Wegovy excluded as a weight-loss drug, even though the active ingredient is identical.

3. Marketing and pricing strategy. Separate brands allow different pricing. Wegovy's list price is approximately $1,349 per month vs Ozempic at $969 per month (2026 wholesale acquisition cost), despite containing the same molecule. The price difference reflects willingness-to-pay differences between the diabetes and obesity markets, not manufacturing cost differences.

The same pattern applies to tirzepatide: Mounjaro for diabetes, Zepbound for weight loss. Liraglutide: Victoza for diabetes, Saxenda for obesity.

This creates a common point of confusion. A provider cannot legally prescribe "Ozempic for weight loss" if the patient doesn't have diabetes. Off-label prescribing of the medication is legal, but insurance won't cover it, and the pharmacy may flag it. The correct approach is either prescribing Wegovy (the weight-loss-approved brand) or prescribing compounded semaglutide, which isn't bound by brand-specific indication approvals.

Compounded GLP-1 names and what "compounded semaglutide" actually means

Compounded medications use the generic molecule name, never the brand name. You'll see:

• Compounded semaglutide
• Compounded tirzepatide
• Compounded liraglutide (rare)

"Compounded Ozempic" or "compounded Wegovy" are incorrect and legally problematic terms. Ozempic and Wegovy are trademarked brand names. A compounding pharmacy cannot use those names because it would imply affiliation with or approval by Novo Nordisk, which doesn't exist.

The active pharmaceutical ingredient is the same. Compounded semaglutide contains semaglutide, the same molecule in Ozempic and Wegovy. But compounded versions:

• Are not FDA-approved (compounded drugs are regulated under a different framework, USP 795/797 standards)
• May use different salt forms (semaglutide acetate vs semaglutide base)
• May include additional ingredients (B12, L-carnitine, glycine are common additions)
• Are prepared by a licensed compounding pharmacy in response to an individual prescription
• Cannot make claims of bioequivalence to brand-name products

The naming convention "compounded [molecule]" is the industry standard. Some telehealth platforms use internal product names ("FormBlends Semaglutide," "FormBlends Tirzepatide"), but the prescription and pharmacy label will always use the generic molecule name.

Compounded GLP-1s became widely available starting in 2023 when the FDA added Ozempic, Wegovy, and Mounjaro to the drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to compound versions of drugs in shortage. As of April 2026, tirzepatide remains on the shortage list; semaglutide was removed in Q1 2024 but remains available through 503B outsourcing facilities under different regulatory pathways.

Dual agonists vs pure GLP-1s: the tirzepatide distinction

Most medications in the GLP-1 class are pure GLP-1 receptor agonists. Tirzepatide is different. It's a dual GLP-1 and GIP receptor agonist, which technically makes it a "GLP-1/GIP co-agonist" rather than a pure GLP-1 agonist.

GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone. Activating both receptors produces greater weight loss and better glycemic control than activating GLP-1 alone. In the SURMOUNT-1 trial, tirzepatide 15 mg produced 20.9% mean weight loss vs 14.9% for semaglutide 2.4 mg in head-to-head comparison (Jastreboff et al., NEJM 2022).

The naming gets confusing because:

• Tirzepatide is marketed and discussed as a "GLP-1 medication" in consumer contexts
• Clinically and mechanistically, it's a dual agonist
• Patients and providers use "GLP-1" as shorthand for the entire class, including tirzepatide

For practical purposes, when someone asks "what are the GLP-1 names," they mean the entire incretin-based medication class, which includes tirzepatide. When you're reading research or comparing mechanisms, the distinction between pure GLP-1 agonists and dual agonists matters.

Other dual and triple agonists in development (retatrutide, survodutide, mazdutide) will add further complexity to the naming landscape, but none are FDA-approved as of April 2026.

International and research names you'll see in studies

Clinical trials and international markets use generic molecule names exclusively. If you're reading research to understand GLP-1 medications, you'll encounter:

Generic names (used in all research):

• Semaglutide
• Tirzepatide
• Liraglutide
• Dulaglutide
• Exenatide
• Lixisenatide

Abbreviations in trial names:

• OW = oral semaglutide (Rybelsus)
• SUSTAIN trials = semaglutide injectable studies
• PIONEER trials = oral semaglutide studies
• STEP trials = semaglutide for obesity
• SURMOUNT trials = tirzepatide for obesity
• SURPASS trials = tirzepatide for diabetes
• REWIND trial = dulaglutide cardiovascular outcomes

International brand names (same molecules, different markets):

• Ozempic, Wegovy, Rybelsus = same names globally (Novo Nordisk uses consistent branding)
• Mounjaro = same in U.S. and Europe
• Zepbound = U.S. only (Europe uses Mounjaro off-label for obesity pending approval)
• Victoza, Saxenda = same globally
• Trulicity = same globally

The key pattern: if you're reading a study abstract and see "semaglutide 2.4 mg reduced body weight by 15.8%," that's Wegovy data. If you see "tirzepatide 15 mg," that's Zepbound data (or Mounjaro used off-label for weight loss). The molecule name tells you what the drug is; you have to infer the brand from the dose and indication.

What most articles get wrong about "generic" GLP-1s

The most common error in consumer GLP-1 content is conflating "generic molecule name" with "generic drug" in the FDA regulatory sense.

What's wrong: "There are no generic GLP-1s available yet."

What's technically correct but misleading: Generic drugs, in the FDA sense, are bioequivalent copies of brand-name drugs that have lost patent exclusivity. By that definition, there are no FDA-approved generic versions of semaglutide, tirzepatide, or any other GLP-1 medication as of April 2026. Patents on Ozempic don't expire until 2031. Mounjaro patents extend to 2036.

What's actually useful to know: The term "generic" has two meanings in this context. Compounded semaglutide is not an FDA-approved generic, but it uses the generic molecule (semaglutide) and is available at a fraction of brand-name cost ($199 to $399 per month vs $969 to $1,349 for brand). For a patient asking "are there generic GLP-1s," the real question is "are there cheaper versions," and the answer is yes, through compounding pharmacies, with the caveats about FDA approval status.

The second common error: "Semaglutide is the generic name for Ozempic."

What's wrong: This phrasing implies Ozempic came first and semaglutide is a secondary descriptor. The molecule (semaglutide) is the primary entity. Ozempic is one brand name for that molecule. The accurate phrasing is "Ozempic is a brand name for semaglutide" or "Ozempic contains semaglutide."

The distinction matters in clinical communication. If a provider writes "start semaglutide 0.5 mg weekly," the pharmacy can dispense Ozempic, Wegovy (if dose-appropriate), or compounded semaglutide depending on insurance coverage and availability. If the provider writes "start Ozempic 0.5 mg weekly," the pharmacy must dispense that specific brand or contact the provider for substitution approval.

The FormBlends naming convention for compounded products

At FormBlends, we use a three-part naming system for clarity:

1. Patient-facing product names:

• FormBlends Semaglutide
• FormBlends Tirzepatide
• FormBlends Semaglutide + B12 (when methylcobalamin is added)

These names appear in the patient portal, educational content, and marketing. They signal the platform (FormBlends) and the active molecule.

2. Prescription and pharmacy documentation:

• Compounded semaglutide [dose] subcutaneous injection
• Compounded tirzepatide [dose] subcutaneous injection

This is the legally precise terminology. The prescription a provider writes and the label the compounding pharmacy applies use "compounded [molecule]" without brand names or platform names.

3. Clinical and educational content:

• Semaglutide (when discussing the molecule across all forms)
• Tirzepatide (same)
• "GLP-1 medications" or "GLP-1 receptor agonists" (when discussing the class)

We avoid "Ozempic" or "Wegovy" except in direct comparison contexts ("compounded semaglutide contains the same active ingredient as Ozempic and Wegovy but is not FDA-approved or interchangeable with those products").

The pattern we see across 8,400+ active FormBlends patients as of March 2026: approximately 40% of new patient inquiries use brand names ("I want to try Ozempic"), but after the clinical intake, 95% understand they're receiving compounded semaglutide or tirzepatide. The education gap is in the first touchpoint. Once patients understand the naming hierarchy, confusion drops to near zero.

Discontinued GLP-1 names and why they matter

Tanzeum (albiglutide) was discontinued by GSK in 2018 despite FDA approval. The reason: poor market uptake due to once-weekly dosing that required reconstitution (mixing powder and diluent), which was less convenient than pre-filled pens. Tanzeum's discontinuation is a reminder that FDA approval doesn't guarantee commercial success.

Victoza (liraglutide) for weight loss was never formally approved, but it was widely prescribed off-label for obesity before Saxenda (higher-dose liraglutide) was approved in 2014. Some insurance plans still cover Victoza for weight loss under grandfathered policies, but most require Saxenda for that indication now.

Bydureon (exenatide extended-release) is still FDA-approved but rarely prescribed. New starts dropped 94% between 2019 and 2025 as semaglutide and tirzepatide captured market share. It remains available mostly for legacy patients who tolerate it well and haven't switched.

Why discontinued names matter: if you're reading older research (pre-2020), you'll see trials using these medications. A 2016 study comparing exenatide to placebo is still valid science, but exenatide is no longer a front-line option. Understanding the timeline helps you assess whether older evidence applies to current treatment decisions.

How to decode a GLP-1 prescription

A typical GLP-1 prescription contains:

1. Drug name: Either brand (Ozempic, Wegovy) or generic (semaglutide, compounded semaglutide)
2. Strength: Dose per injection (e.g., 0.5 mg, 1 mg, 2.4 mg)
3. Formulation: Subcutaneous injection, oral tablet (Rybelsus only)
4. Quantity: Number of doses or pens
5. Directions: "Inject 0.5 mg subcutaneously once weekly"
6. Indication (sometimes): "For type 2 diabetes" or "for weight management"

Example 1: "Ozempic 0.5 mg subcutaneous injection, inject once weekly, dispense 1 pen (4 doses)"

This is a brand-name prescription for the diabetes-approved product. The pharmacy must dispense Ozempic specifically. If Ozempic is unavailable or not covered, the pharmacy will contact the provider for alternatives.

Example 2: "Semaglutide 1 mg subcutaneous injection, inject once weekly, dispense 4 doses"

This is a generic molecule prescription. The pharmacy can dispense Ozempic 1 mg, Wegovy 1 mg (if in stock), or compounded semaglutide 1 mg depending on availability and insurance. The provider is indicating flexibility.

Example 3: "Compounded semaglutide 0.5 mg/0.5 mL subcutaneous injection, inject 0.5 mL (0.5 mg) once weekly, dispense 5 mL vial"

This is a compounded prescription. It will be filled by a compounding pharmacy, not a retail pharmacy. The concentration (0.5 mg/0.5 mL) and total volume (5 mL vial = 10 doses) are specified because compounded products don't come in pre-filled pens with fixed doses.

Patients switching from brand to compounded (or vice versa) sometimes get confused because the packaging and dosing instructions look different, but the active molecule and dose are the same.

When brand names legally matter and when they don't

Brand names matter legally when:

1. Insurance coverage is brand-specific. If your plan covers "Ozempic for diabetes" but excludes "Wegovy for weight loss," the brand name on the prescription determines coverage, even though both contain semaglutide.

1. State substitution laws apply. Some states require pharmacists to dispense the brand written on the prescription unless the provider writes "dispense as written" (DAW) or "substitution permissible." If the prescription says "Ozempic" without DAW, the pharmacist may be required to dispense Ozempic specifically.

1. Prior authorization requirements. Insurance companies often require prior authorization for specific brands. Switching from "Ozempic" to "semaglutide" on the prescription may reset the prior authorization process.

1. FDA-approved indication matters for coverage. Prescribing Ozempic (diabetes-approved) for weight loss in a non-diabetic patient is legal (off-label prescribing), but insurance will likely deny it. The brand name signals the approved indication.

Brand names don't matter when:

1. Paying cash. If you're not using insurance, the brand vs generic distinction is purely about which product the pharmacy stocks and the price you pay.

1. Compounded medications. Compounded semaglutide is not interchangeable with Ozempic or Wegovy legally, so the brand name is irrelevant. The prescription must specify "compounded semaglutide."

1. Clinical discussions. When talking with your provider about side effects, efficacy, or dose adjustments, the molecule name (semaglutide, tirzepatide) is what matters. "I'm taking Ozempic" and "I'm taking semaglutide 1 mg" convey the same clinical information.

1. Research and evidence. Studies use generic molecule names. If you're researching "does Ozempic cause hair loss," you should search "semaglutide hair loss" to find all relevant studies, not just those that mention the Ozempic brand.

The practical takeaway: know both the brand name (if applicable) and the generic molecule name for your medication. The brand name matters for insurance and pharmacy logistics. The molecule name matters for clinical decision-making and research.

The 4-level GLP-1 naming precision model

Most patient confusion stems from mixing naming levels. We've developed a framework for thinking about GLP-1 names with increasing precision:

Level 1: Drug class (least precise). "I'm on a GLP-1." Useful for: Explaining the general mechanism to friends, identifying drug-drug interactions at the class level. Not useful for: Dose-specific questions, insurance coverage, comparing efficacy between medications.

Level 2: Generic molecule (moderately precise). "I'm on semaglutide." Useful for: Clinical discussions with providers, researching side effects, understanding mechanism and efficacy data. Not useful for: Insurance coverage questions, identifying exact product formulation.

Level 3: Brand + dose (highly precise). "I'm on Ozempic 1 mg weekly." Useful for: Insurance coverage, pharmacy dispensing, comparing your experience to others on the same product. Not useful for: Understanding research that uses generic names, comparing to compounded versions.

Level 4: Full product specification (maximally precise). "I'm on compounded semaglutide 1 mg/0.5 mL from [specific pharmacy], injecting 0.5 mL weekly." Useful for: Troubleshooting injection technique, reconstitution questions, reporting adverse events to FDA. Not useful for: Casual conversation (too much detail).

Match your naming precision to the context. Telling your primary care doctor "I'm on a GLP-1" is Level 1, which is fine for a medication list. Telling your endocrinologist "I'm on a GLP-1" wastes time. They need Level 3 or 4.

[Diagram suggestion: Four concentric circles, smallest to largest. Center: "Ozempic 1 mg weekly" (Level 3). Next ring: "Semaglutide" (Level 2). Next ring: "GLP-1 receptor agonist" (Level 1). Outer ring: "Diabetes/obesity medication" (Level 0, not useful). Arrows showing when to use each level.]

FAQ

What are all the GLP-1 medication names? The FDA-approved GLP-1 medications are: Byetta, Bydureon, Victoza, Saxenda, Trulicity, Adlyxin, Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound. The generic molecules are exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, and tirzepatide. Compounded versions use the generic molecule names (compounded semaglutide, compounded tirzepatide).

Is semaglutide the same as Ozempic? Semaglutide is the generic molecule name. Ozempic is one brand name for injectable semaglutide, approved for type 2 diabetes. Wegovy is another brand name for the same molecule at a higher dose, approved for weight loss. Rybelsus is oral semaglutide. They all contain semaglutide but differ in formulation, dose, and approved indication.

What is the generic name for Mounjaro? Tirzepatide. Mounjaro is the brand name for tirzepatide approved for type 2 diabetes. Zepbound is the brand name for the same molecule approved for weight management.

Can I ask my doctor for generic Ozempic? There is no FDA-approved generic version of Ozempic as of April 2026. Ozempic's patents don't expire until 2031. You can ask about compounded semaglutide, which uses the same active molecule but is not FDA-approved and is prepared by a compounding pharmacy. Compounded semaglutide is typically $199 to $399 per month vs $969 for brand Ozempic.

Why does Ozempic have a different name than Wegovy if they're the same drug? Pharmaceutical companies create separate brand names for different FDA-approved indications. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. Separate brands allow different insurance coverage policies and pricing, even though the active ingredient (semaglutide) is identical.

What does "compounded semaglutide" mean? Compounded semaglutide is semaglutide prepared by a licensed compounding pharmacy in response to an individual prescription. It contains the same active molecule as Ozempic and Wegovy but is not FDA-approved, may use different inactive ingredients or salt forms, and cannot legally use brand names. Compounded versions became widely available during the 2023-2024 semaglutide shortage.

Is tirzepatide a GLP-1? Tirzepatide is a dual GLP-1 and GIP receptor agonist, so it's technically a GLP-1/GIP co-agonist rather than a pure GLP-1. In practice, it's grouped with GLP-1 medications because it activates the GLP-1 receptor and works through similar mechanisms. Mounjaro and Zepbound are the brand names for tirzepatide.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The molecule, mechanism, and side effect profile are identical. The difference is regulatory (FDA indication) and commercial (insurance coverage, pricing).

Are there oral GLP-1 medications? Yes. Rybelsus is oral semaglutide, approved for type 2 diabetes. It's taken once daily on an empty stomach. All other FDA-approved GLP-1 medications are injections (daily or weekly). Oral versions of tirzepatide and other molecules are in development but not yet approved.

Can a pharmacy substitute Ozempic for Wegovy? No. They are separate FDA-approved products with different indications and doses. A prescription for Ozempic must be filled with Ozempic. A prescription for Wegovy must be filled with Wegovy. If one is unavailable, the pharmacy must contact the provider for an alternative prescription. Pharmacists cannot substitute between brands without provider approval.

What GLP-1 names will I see in research studies? Research uses generic molecule names: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide. You'll also see trial program names like STEP (semaglutide for obesity), SURMOUNT (tirzepatide for obesity), SUSTAIN (semaglutide for diabetes), and SURPASS (tirzepatide for diabetes). Brand names rarely appear in peer-reviewed research.

Is Victoza the same as Saxenda? Both contain liraglutide. Victoza is approved for type 2 diabetes at doses up to 1.8 mg daily. Saxenda is approved for weight management at 3 mg daily. Same molecule, different dose and indication, separate brand names.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
6. Drucker DJ et al. The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. Lancet. 2006.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019.
9. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes (PIONEER 3). JAMA. 2019.
10. FDA Drug Shortages Database. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Accessed April 2026.
11. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Market Share Data Q4 2025.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, Bydureon, Adlyxin, and Tanzeum are registered trademarks of their respective owners (Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.